IceCure Medical Ltd. (ICCM)
NASDAQ (CM) NASDAQ (CM) Primary 
IceCure Secures China NMPA Approval for ProSense Cryoablation System
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03.
IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript
IceCure Medical (ICCM) Projected to Post Earnings on Tuesday
IceCure Medical (NASDAQ: ICCM - Get Free Report) is expected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect IceCure Medical to post earnings of ($0.04) per share and revenue of $1.30 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q4 2025 earning overview
IceCure Medical Ltd - Special Call
IceCure Medical Ltd - Special Call Company Participants Eyal Shamir - CEO & Director Shad Good Ronen Tsimerman - CFO & COO Conference Call Participants Michael Polyviou - EVC Group Inc. Anthony Vendetti - Maxim Group LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Good morning, and thank you for standing by. [Operator Instructions] Please be advised that today's conference call is being recorded.
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment
IceCure Medical shares surge after FDA clears ProSense, marking the first minimally invasive breast cancer treatment for women aged 70 and above.
IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM ) Q2 2025 Earnings Conference Call August 13, 2025 10:00 AM ET Company Participants Michael Polyviou - IR, EVC Group Inc. Eyal Shamir - CEO & Director Ronen Tsimerman - CFO & COO Conference Call Participants Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Anthony V. Vendetti - Maxim Group LLC, Research Division Eduardo Rafael Martinez-Montes - H.C.
IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates
IceCure Medical Ltd. (ICCM) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share.
IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2025 Earnings Conference Call May 28, 2025 10:00 AM ET Company Participants Michael Polyviou - IR Eyal Shamir - CEO Ronen Tsimerman - CFO and COO Conference Call Participants Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Good morning, and thank you for standing by. Currently, all the participants are in a listen-only mode.
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results
ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.
